Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-21
2006-11-21
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253010, C514S253130
Reexamination Certificate
active
07138396
ABSTRACT:
There are disclosed compounds of the formula (I):prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17β-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.
REFERENCES:
patent: 5350852 (1994-09-01), Emonds-Alt et al.
patent: 5432175 (1995-07-01), Piwinski et al.
patent: 5620989 (1997-04-01), Harrison et al.
patent: 5654316 (1997-08-01), Carruthers et al.
patent: 5665735 (1997-09-01), Friary et al.
patent: 5688960 (1997-11-01), Shankar
patent: 5691362 (1997-11-01), McCormick et al.
patent: 5696267 (1997-12-01), Reichard et al.
patent: 5719156 (1998-02-01), Shue et al.
patent: 5760018 (1998-06-01), Baker et al.
patent: 5783579 (1998-07-01), McCormick et al.
patent: 5789422 (1998-08-01), Reichard et al.
patent: 5840725 (1998-11-01), Reichard et al.
patent: 5945428 (1999-08-01), Shih et al.
patent: 5968929 (1999-10-01), Blythin et al.
patent: 6063926 (2000-05-01), Reichard et al.
patent: 6204265 (2001-03-01), Reichard et al.
patent: 6391865 (2002-05-01), Baroudy et al.
patent: 1 122 242 (1999-09-01), None
patent: WO 86/01105 (1986-02-01), None
patent: WO 90/10462 (1990-09-01), None
patent: WO 91/00731 (1991-01-01), None
patent: WO 91/00733 (1991-01-01), None
patent: WO 94/10165 (1994-05-01), None
patent: WO 94/13639 (1994-06-01), None
patent: WO 94/26767 (1994-11-01), None
patent: WO 94/29309 (1994-12-01), None
patent: WO 95/19344 (1995-07-01), None
patent: WO 96/26201 (1996-08-01), None
patent: WO 97/11162 (1997-03-01), None
patent: WO 00/43008 (2000-07-01), None
patent: WO 01/58891 (2001-08-01), None
Hawley's Condensed Chemical Dictionary, 12th ed., Richard J. Lewis, Sr. , © 1993 by Van Nostrand Reinhold, p. 594.
Concise Chemical Dictionary, edited by Drs. Hans-Dieter Jakubke and Hans Jeschkeit, © 1993 by Walter de Gruyter & Co., p. 490.
McGraw-Hill Dictionary of Chemical Terms, 3rd ed. edited by Sybil P. Parker, © 1984 McGraw-Hill, Inc., p. 200.
Mallams et al, J. Med. Chem. vol. 41, pp. 877-893 (1998).
Debeljuk, L., et al., “Modulation of the hypothalamo-pituitary-gonadal axis and the pineal gland by neurokinin A, neuropeptide K and neuropeptide γ,”Peptides20:285-299 (1999).
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10thed., McGraw-Hill Medical Publishing Division © 2001, pp. 1635-1648.
Hawley's Condensed Chemical Dictionary, 12thed., Richard J. Lewis, Sr., © 1993 by Van Nostrand Reinhold, p. 594.
McGraw-Hill Dictionary of Chemical Terms, 3rded., edited by Sybil P. Parker, © 1984 McGraw-Hill, Inc., p. 200.
Mallams, et al.,J. Med. Chem.,41:877-893 (1998).
Poirier, Donald, “Inhibitors of 17-beta-Hydroxysteroid Dehydrogenases,”Current Medicinal Chemistry10:453-477 (2003).
Smith, et al., “Inhibitors of steroidgenesis as agents for the treatment of hormone-dependent cancers,”Expert Opinion on Therapeutic Patients,11(5):789-824 (2001).
The Merck Manual, 16thed., pp. 1092-1093, 2277-2278 and 2429-2431, Merck Research Laboratories, Merck & Co., Rahway, NJ © 1992.
Doll Ronald J.
Girijavallabhan Viyyoor M.
Guzi Timothy J.
Liu Yi-Tsung
Mallams Alan K.
Kalyanaraman Palaiyur S.
Schering Corporation
Tucker Zachary C.
Wilson James O.
LandOfFree
17 β-hydroxysteroid dehydrogenase type 3 inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 17 β-hydroxysteroid dehydrogenase type 3 inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17 β-hydroxysteroid dehydrogenase type 3 inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3663006